GENE ONLINE|News &
Opinion
Blog

2021-05-27| Special

10 Precision Oncology Companies to Look Out for

by Rajaneesh K. Gopinath
Share To
According to statistics, the global precision oncology market is forecast to reach US$ 99.72 billion by 2027. Several established giants in the cancer genomics space like Illumina, Roche, Qiagen, Thermo Fisher Scientific, and Merck are positioned to soar even higher.

However, a number of promising startups that burst into the scene in the last decade and a half have attracted new capital and have extended newer technologies. Here we list 10 such precision oncology companies to look out for.

GO Prime with only $1.49 now

LATEST
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlightll In $970 Million Pact
2023-03-23
FDA Extends Approval Of Regeneron’s Evkeeza For Inherited High Cholesterol
2023-03-23
Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.
2023-03-23
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
2023-03-22
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Scroll to Top